Neola Medical AB (publ) (STO:NEOLA)
Sweden flag Sweden · Delayed Price · Currency is SEK
1.160
+0.020 (1.75%)
May 25, 2026, 5:29 PM CET

Neola Medical AB Income Statement

Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
8.988.2810.079.789.4410.38
Other Revenue
-0.02-0.050.040.30.74
8.978.2810.129.839.7411.13
Revenue Growth (YoY)
1.43%-18.13%2.97%0.84%-12.43%280.64%
Cost of Revenue
0.20.271.371.771.421.33
Gross Profit
8.778.018.758.068.329.8
Selling, General & Admin
19.3917.7618.2316.0917.6416.39
Other Operating Expenses
-0.05-0.05-0.21-0.030.04
Operating Expenses
20.7619.119.5517.6918.4416.45
Operating Income
-11.99-11.09-10.8-9.63-10.12-6.65
Interest & Investment Income
0.070.070.730.610.03-
Currency Exchange Gain (Loss)
---0--
Other Non Operating Income (Expenses)
-0.04----0-
EBT Excluding Unusual Items
-11.95-11.02-10.06-9.01-10.09-6.65
Asset Writedown
-----0.27-
Pretax Income
-11.95-11.02-10.06-9.01-10.35-6.65
Net Income
-11.95-11.02-10.06-9.01-10.35-6.65
Net Income to Common
-11.95-11.02-10.06-9.01-10.35-6.65
Shares Outstanding (Basic)
-7770562614
Shares Outstanding (Diluted)
-7770562614
Shares Change (YoY)
-9.27%25.80%113.90%86.03%48.67%
EPS (Basic)
--0.14-0.14-0.16-0.40-0.47
EPS (Diluted)
--0.14-0.14-0.16-0.40-0.47
Free Cash Flow
-13.02-11.95-10.92-6.54-8.6-7.1
Free Cash Flow Per Share
--0.16-0.16-0.12-0.33-0.51
Gross Margin
97.81%96.69%86.47%82.04%85.41%88.05%
Operating Margin
-133.66%-133.93%-106.73%-97.97%-103.86%-59.80%
Profit Margin
-133.27%-133.07%-99.48%-91.70%-106.26%-59.80%
Free Cash Flow Margin
-145.16%-144.30%-107.90%-66.59%-88.27%-63.83%
EBITDA
-10.6-9.71-9.4-8.19-9.55-6.64
EBITDA Margin
-118.20%-117.20%-92.95%-83.39%-98.00%-59.66%
D&A For EBITDA
1.391.391.391.430.570.02
EBIT
-11.99-11.09-10.8-9.63-10.12-6.65
EBIT Margin
-133.66%-133.93%-106.73%-97.97%-103.86%-59.80%
Revenue as Reported
9.018.33--9.7511.1
Source: S&P Global Market Intelligence. Standard template. Financial Sources.